Pharmaceuticals, Biotechnology & Life Sciences

Merck’s acquisition of Terns Pharmaceuticals clears a key antitrust hurdle, potentially boosting its specialty drug portfolio and valuation while navigating Medicare reimbursement and breakthrough therapy benefits.

WuXi AppTec Q1 2026 results show 30 % revenue jump, 26 % profit rise, and 70 % adjusted earnings boost, driving CDMO growth, cost savings, and investor confidence.

Otsuka Holdings’ Q1 earnings grow, while Taiho’s ARC‑02 ADC moves to Phase‑1 and Pharmavite leads bone‑health supplements—showing a balanced, growth‑oriented strategy across pharma and nutraceuticals.

Explore why Insmed Inc. ranks as a top upside‑potential holding in QQQ, with strong rare‑disease pipeline, growth outlook, and partnership prospects.

Galderma’s April 27 share rise signals investor trust as it pivots from injectables to energy‑based aesthetic treatments, tackling patent cliffs, pricing resilience, and M&A to secure future growth in Switzerland’s competitive pharma market.

Explore how Haleon’s share buybacks and bone‑health supplements impact investors and patients alike, with key market insights and safety data.

AbbVie’s FDA filing for subcutaneous SKYRIZI® could slash induction costs by 50 %, boost patient adherence, and expand IBD market reach.

German markets see modest gains as Sartorius AG’s analyst upgrade fuels a strong rally, highlighting how positive research sentiment can boost the TecDAX and MDAX indices.

How the Supreme Court’s Roundup ruling could cost Bayer AG $3‑$5 bn, shift agro‑chemical regulation and raise healthcare supply‑chain costs.

Merck KGaA’s modest share drop on 27 Apr 2026 stems mainly from ex‑dividend mechanics, not fundamentals. Despite a €2.20 payout, the company’s solid market cap, regulatory resilience, and growth prospects in digital health and sustainable chemistry …